NanoLogix Inc. Files Multiple International Patent Applications for BioNanoChannel(TM) and Hydrogen Bioreactor Technology
November 28 2007 - 10:00AM
PR Newswire (US)
HUBBARD, Ohio, Nov. 28 /PRNewswire-FirstCall/ -- NanoLogix, Inc.
(OTC:NNLXOTC:-OTC:News) a nano-biotechnology company announces that
the company has submitted international patent applications for
BioNanoChannel(TM) and Hydrogen Bioreactor technology protection
for China, India, Brazil, and the EU (European Union). These
filings are necessary prior to the anticipated global roll-out of
the company's BioNanoChannel(TM) rapid bacteria/microorganism
detection technology and also contribute to the protection of
NanoLogix's ongoing Hydrogen Bioreactor development. Chris Novak,
NanoLogix Director of IP stated: "The strength and improved focus
of the new foreign cases arose from significant improvements to the
originally filed provisional patent applications. We at NanoLogix
are very excited about the potential for enhancing the patent
protection for these new technologies." According to Bret
Barnhizer, NanoLogix President and CEO, "This is a step forward for
the company in its plans for technological and business development
and sets the stage for one of our corporate goals of pursuing
licensing opportunities for use of our products internationally.
These applications aid us by ensuring that NanoLogix strengthens
their control over the intellectual property rights to the
technology." About NanoLogix, Inc. NanoLogix is a leading innovator
in the research, development, and commercialization of
nano-biotechnologies, applications and processes. The Company has
31 granted Patents and 36 Patents Pending for bioreactor-based
Hydrogen Production, revolutionary rapid medical testing
technologies, potential treatments for sepsis and cancer (via
apoptosis), and bioremediation. Information on NanoLogix is
available at http://www.nanologixinc.com/. This press release
contains statements, which may constitute "forward- looking
statements" within the meaning of the Securities Act of 1933 and
the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Those statements include
statements regarding the intent, belief or current expectations of
NanoLogix, Inc., and members of its management as well as the
assumptions on which such statements are based. Prospective
investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from
those contemplated by such forward-looking statements. The Company
undertakes no obligation to update or revise forward-looking
statements to reflect changed assumptions, the occurrence of
unanticipated events or changes to future operating results.
Contact: Investor Relations Bret Barnhizer, CEO Telephone:
330-534-0800 E-mail: DATASOURCE: NanoLogix, Inc. CONTACT: Bret
Barnhizer, CEO of NanoLogix, Inc., +1-330-534-0800, Web site:
http://www.nanologixinc.com/
Copyright